Cerity Partners
IONS icon

Cerity Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Cerity Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$570K Sell
7,596
-16,331
-68% -$1.29M ﹤0.01% 2203
2025
Q4 		$1.89M Buy
+23,927
New +$1.8M ﹤0.01% 1399

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cerity Partners's IONS Position: Q1 2026 in Review

Cerity Partners reduced its Ionis Pharmaceuticals (IONS) stake by 68% in Q1 2026, selling an estimated $1.29M and leaving 7,596 shares worth $570K. The position accounts for ﹤0.01% of the portfolio, ranked #2203.

Cerity Partners first reported a position in IONS in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.89M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Cerity Partners held 7,596 shares of Ionis Pharmaceuticals worth $570K as of Q1 2026.
  • Cerity Partners sold 16,331 Ionis Pharmaceuticals shares in Q1 2026, an estimated $1.29M.
  • Ionis Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2203 holding.
  • Cerity Partners first reported a position in Ionis Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Cerity Partners's Ionis Pharmaceuticals position peaked at $1.89M in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.